Abstract
Recent adoption of a new thyroid cytopathology reporting system (the Bethesda system) and current clinical practice guidelines have led to a large number of patients with indeterminate thyroid nodules undergoing diagnostic thyroid lobectomy. If such patients are found to have papillary thyroid cancer on final pathology, the question of completion thyroidectomy is often raised. In general, patients who have undergone a lobectomy in this situation and are found to have thyroid cancer will typically have low-risk disease. In such cases, there is little compelling evidence to recommend completion thyroidectomy, to either decrease recurrence rates or allow radioiodine remnant ablation. Therefore, for patients with low-risk thyroid cancer who have undergone lobectomy, follow-up without additional surgery, using serum thyroglobulin measurements and neck ultrasound to monitor for recurrence, is recommended.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol. 2012;56:333–9.
Patel KN, Angell TE, Babiarz J, et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg. 2018;153:817–24.
Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol. 2019;5:204–12.
Park S, Jeon MJ, Oh HS, et al. Changes in serum thyroglobulin levels after lobectomy in patients with low-risk papillary thyroid cancer. Thyroid. 2018;28:997–1003.
Kim ES, Kim TY, Koh JM, Kim YI, Hong SJ, Kim WB, Shong YK. Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol. 2004;61:145–8.
Vaisman F, Shaha A, Fish S, Tuttle RM. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol. 2011;75:112–9.
Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, Tufano RP, Tuttle RM, American Thyroid Association Surgical Affairs Committee’s Taskforce on Thyroid Cancer Nodal Surgery. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22:1144–52.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.
Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124:958–64.
Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Sturgeon C. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–81.
Shaha AR. Extent of surgery for papillary thyroid carcinoma: the debate continues: comment on “surgery for papillary thyroid carcinoma”. Arch Otolaryngol Head Neck Surg. 2010;136:1061–3.
Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136:1055–61.
Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Shah JP. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012;151:571–9.
Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601–7.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.
Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014;21:3844–52.
Untch BR, Palmer FL, Ganly I, Patel SG, Tuttle RM, Shah JP, Shaha AA. Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma. Ann Surg Oncol. 2014;21:1374–8.
Nikiforov YE. Role of molecular markers in thyroid nodule management: then and now. Endocr Pract. 2017;23:979–88.
Lee DY, Seok J, Jeong WJ, Ahn SH. Prediction of thyroid hormone supplementation after thyroid lobectomy. J Surg Res. 2015;193:273–8.
Zatelli MC, Lamartina L, Meringolo D, et al. Thyroid nodule recurrence following lobo-isthmectomy: incidence, patient’s characteristics, and risk factors. J Endocrinol Investig. 2018;41:1469–75.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Cooper, D.S. (2021). Completion Thyroidectomy in a Patient with Low-Risk Papillary Cancer. In: Grani, G., Cooper, D.S., Durante, C. (eds) Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-61919-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-61919-0_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-61918-3
Online ISBN: 978-3-030-61919-0
eBook Packages: MedicineMedicine (R0)